<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>338</serviceExecutionTime><Drug id="2776"><DrugName>talizumab</DrugName><DrugNamesKey><Name id="42754173">talizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>TNX-901</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>talizumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>AL-901</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>HU-901</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CGP-51901</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-IgE MAbs, Tanox</Value></Name><Name><Value>anti-allergy MAbs, Tanox</Value></Name></DrugSynonyms><CompanyOriginator id="20318">Tanox Inc</CompanyOriginator><CompaniesSecondary><Company id="20318">Tanox Inc</Company><Company id="24437">Ciba-Geigy AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2776" type="Drug"><TargetEntity id="192148" type="siDrug">Talizumab</TargetEntity></SourceEntity><SourceEntity id="20318" type="Company"><TargetEntity id="4295916041" type="organizationId">Tanox Inc</TargetEntity></SourceEntity><SourceEntity id="24437" type="Company"><TargetEntity id="4295890636" type="organizationId">Ciba Geigy AG</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="507" type="ciIndication"><TargetEntity id="10002199" type="MEDDRA"></TargetEntity><TargetEntity id="-2042429199" type="omicsDisease"></TargetEntity><TargetEntity id="1884" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1747" type="Action"><TargetEntity id="3700" type="Mechanism">Anti-IgE</TargetEntity><TargetEntity id="4322" type="Mechanism">Anti-IgE (Fc Region)</TargetEntity><TargetEntity id="1112" type="Mechanism">Immunoglobulin E (IgE) Production Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1107">Allergic rhinitis</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="31">Asthma</Indication><Indication id="507">Immediate type hypersensitivity</Indication></IndicationsSecondary><ActionsPrimary><Action id="1747">Immunoglobulin E antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-30T16:16:30.000Z</LastModificationDate><ChangeDateLast>2018-03-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Talizumab (HU-901, TNX-901), a humanized version of the anti-IgE monoclonal antibody AL-901, was being developed by &lt;ulink linkID="20318" linkType="Company"&gt;Tanox&lt;/ulink&gt; for the potential treatment of IgE-mediated inflammatory diseases, including allergies. By July 1999, it was in phase II trials for severe peanut allergy; at that time, completion was expected in the third quarter of 2001 [&lt;ulink linkID="331745" linkType="reference"&gt;331745&lt;/ulink&gt;], [&lt;ulink linkID="397575" linkType="reference"&gt;397575&lt;/ulink&gt;]. In March 2003, clinical studies were put on hold due to a legal dispute between Tanox, &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; and &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; [&lt;ulink linkID="481301" linkType="reference"&gt;481301&lt;/ulink&gt;]; the dispute was resolved in February 2004 [&lt;ulink linkID="596926" linkType="Reference"&gt;596926&lt;/ulink&gt;] but, in March 2005, development was said to be "winding down" and the program was no longer listed by Tanox [&lt;ulink linkID="596927" linkType="Reference"&gt;596927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Talizumab was previously being codeveloped with Ciba (now &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;) for allergic rhinitis and asthma, but these indications were discontinued after the Tanox/Ciba and Genentech anti-IgE antibody programs were merged in July 1996, following settlement of lawsuits, and Genentech's &lt;ulink linkID="2534" linkType="Drug"&gt;omalizumab&lt;/ulink&gt; (qv) was selected as the most promising lead candidate for these indications [&lt;ulink linkID="263801" linkType="Reference"&gt;263801&lt;/ulink&gt;], [&lt;ulink linkID="277691" linkType="reference"&gt;277691&lt;/ulink&gt;], [&lt;ulink linkID="322048" linkType="reference"&gt;322048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, the FDA granted talizumab Fast Track status for the treatment of patients with peanut allergies [&lt;ulink linkID="464974" linkType="reference"&gt;464974&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2003, clinical data on talizumab were presented at the 60th Annual AAAAI meeting in Denver, CO. In a randomized, double-blinded, placebo-controlled study, 82 individuals (aged 12 to 60 years) with severe peanut allergy were given four injections at monthly intervals of either placebo or talizumab (150, 300 or 450mg).  Each challenge was halted and treatment began as soon as an allergic reaction had begun. The compound was well tolerated and had no significant side effects. The threshold sensitivity to peanut flour, for patients receiving the largest dose (450 mg) of talizumab increased from an average of 177 mg to 2805 mg. Nearly a quarter of the patients receiving the highest dose of talizumab consumed 8000 mg, or about 24 peanuts, with no adverse reaction. More peanuts could be consumed after injection before allergic reaction occurred [&lt;ulink linkID="484636" linkType="reference"&gt;484636&lt;/ulink&gt;]. Similar data were presented in June 2004 at the 23rd European Academy of Allergology and Clinical Immunology meeting in Amsterdam, the Netherlands [&lt;ulink linkID="546936" linkType="reference"&gt;546936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2003, researchers conducting a study of anti-IgE therapy in patients with peanut allergy revealed that talizumab significantly boosted patient sensitivity from half a peanut to almost 9 peanuts [&lt;ulink linkID="481301" linkType="reference"&gt;481301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, preliminary results from the phase II peanut allergy trial were disclosed. The trial involved 84 patients in 4 dose groups (0, 150, 300 and 450 mg). Talizumab significantly increased symptom threshold to peanuts by oral food challenge. Detailed study results were to be reported later in the year [&lt;ulink linkID="450182" linkType="reference"&gt;450182&lt;/ulink&gt;]. Tanox has stated that the trial met its primary endpoint with statistical significance [&lt;ulink linkID="464974" linkType="reference"&gt;464974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The initiation of a phase IIa study of talizumab for the treatment of asthma had been announced in May 1996. The placebo-controlled study was planned to involve a total of approximately 320 patients with mild-to-moderate asthma, elevated blood IgE levels and skin test sensitivity to house dust mites, cockroaches, dogs or cats. The aims were to assess the effect of the treatment on asthma symptoms and airflow in the lungs, and to evaluate the safety and tolerability of multiple doses of the product in patients with asthma [&lt;ulink linkID="206946" linkType="reference"&gt;206946&lt;/ulink&gt;]. Tanox had initiated this study by July 1996 when it was announced that the company was to combine its anti-IgE antibody program for asthma and allergic rhinitis with &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt;'s [&lt;ulink linkID="277691" linkType="reference"&gt;277691&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By November 1994, the company had completed a phase II trial of talizumab in the US in 155 patients with a history of seasonal allergic rhinitis. The study measured elevated blood IgE levels and skin reactivity to mountain cedar pollen [&lt;ulink linkID="180397" linkType="reference"&gt;180397&lt;/ulink&gt;]. The results showed that the treatment reduced the severity and duration of nasal symptoms compared to placebo. Those in the treated group also used less rescue medicines [&lt;ulink linkID="191533" linkType="reference"&gt;191533&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;AL-901 was claimed to be specific for circulating IgE and IgE bound by B cells, rather than IgE that is located on the surface of basophils or mast cells. It therefore initiates the downregulation or death of the B cells and clears circulating IgE without initiating the release of histamines and other substances which trigger allergic symptoms [&lt;ulink linkID="180511" linkType="reference"&gt;180511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, in connection with a 1999 lawsuit filed against &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; and &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, relating to Tanox's right to independently develop AL-901, Tanox declared that the US District Court for the Northern District of California found that "Tanox's right to independently develop certain anti-IgE antibodies [is] clear." The Court also ruled that, in connection with those development efforts, Tanox may use information acquired under its tripartite agreement with &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; and &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; [&lt;ulink linkID="425372" linkType="reference"&gt;425372&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2000, Tanox received a $95,000 grant from The Peanut Foundation in support of the ongoing phase I/II trials [&lt;ulink linkID="370791" linkType="reference"&gt;370791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1995, Ciba had obtained worldwide marketing rights to talizumab and its humanized form, with Tanox retaining rights to copromote in the US and comarket in China, Korea, Taiwan, Hong Kong and Singapore [&lt;ulink linkID="180364" linkType="reference"&gt;180364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 1994, Tanox had established a laboratory scale production and purification facility for talizumab and related products, producing sufficient material for clinical trials, and was considering a joint venture pilot facility with Ciba for larger scale production [&lt;ulink linkID="173036" linkType="reference"&gt;173036&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition to the associated patent, WO-09111456, Tanox holds a related patent, WO-09015614, which claims antibodies specific for immunoglobulin-A-bearing B cells. A Ciba-Geigy patent, EP-00396505, that claimed monoclonal antibodies has been withdrawn.&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Nestor A Molfino, MD, MSc (Immunol), &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt;, Quebec, Canada&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;7 August 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;AL-901 (CGP-51901), is an anti-IgE monoclonal antibody which is being developed for the treatment of IgE-mediated atopic conditions, such as allergic rhinitis, asthma and atopic dermatitis. Because AL-901 not only binds to the Fc portion of IgE, but also to circulating IgE, it does not trigger the production of inflammatory mediators whilst reducing blood levels and the production of IgE. AL-901 may become an alternative therapeutic choice [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;], since it also offers the clinical, theoretical advantage of being effective in a non-allergen specific manner [&lt;ulink linkType="reference" linkID="155434"&gt;155434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AL-901 is under development by Tanox Biosystems [&lt;ulink linkType="reference" linkID="180511"&gt;180511&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="180513"&gt;180513&lt;/ulink&gt;] and in 1990, Ciba (&lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;) obtained worldwide marketing rights [&lt;ulink linkType="reference" linkID="177071"&gt;177071&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="180364"&gt;180364&lt;/ulink&gt;]. In 1996, &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt; (Roche) and Tanox agreed to codevelop their anti-IgE antibodies in a joint program [&lt;ulink linkType="reference" linkID="263801"&gt;263801&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The synthesis of AL-901 is based on the concept of a monoclonal antibody directed to the IgE-Fc region involved in the binding of IgE to the IgE receptor types I and II. Such an antibody should bind specifically to IgE and to IgE-expressing cells. However, it should not bind to cells bearing IgE bound to the high affinity IgE receptor, FcepsilonRI, and therefore, it should not induce histamine release nor bind to the low affinity IgE receptor, FcepsilonRII, on lymphocytes and monocytes [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;]. In addition, the preferred MAb against IgE should have the biological properties of human IgG1, so that it can effectively mediate complement-dependent and cellular cytotoxicity to facilitate the elimination of IgE-producing cells. &lt;/para&gt;&lt;para&gt;AL-901 has been synthesized by standard procedures for the generation of chimeric (murine-human) antibodies [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In vitro and in vivo studies to characterize the pharmacological properties of AL-901 have been reported [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;]. It has been shown that AL-901 binds to human IgE, from various sources, in a dose-dependent manner, that it does not bind to other human or non-human immunoglobulins, that its binding affinity for circulating IgE is high (up to 90%, with a concentration of 1 microg/ml), that a concentration of 1 microg/ml can be reached with an iv dose of 3 mg, in an average adult, that it binds to two sites on IgE, but no complement cascade is activated, that it binds to IgE-secreting cells, that it does not induce histamine release, and that it does not bind to IgE that is bound to FcepsilonRII. Overall, these properties can theoretically elicit a reduction of circulating IgE and can provoke the death of IgE-secreting B-cells. &lt;/para&gt;&lt;para&gt;Although this biological concept has been tested in animal models using other anti-IgE MAbs [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;], AL-901 has been shown to prevent the growth of tumors that have been genetically engineered to express human IgE on the cell surface. In mice, a 200 microg dose of AL-901 blocked the binding of IgE, enhancing clearance of serum IgE and depleting IgE-producing B-cell levels [&lt;ulink linkType="reference" linkID="159999"&gt;159999&lt;/ulink&gt;]. AL-901 binds to IgE-producing B-cells and triggers down-regulation or apoptosis of such cells, thereby reducing circulating IgE levels. Because AL-901 does not bind to IgE located on the cell surface, it does not cross-link IgE and it does not elicit degranulation and release of histamine and other allergic inflammatory mediators [&lt;ulink linkType="reference" linkID="180511"&gt;180511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The stability of a solution of AL-901 was studied by HPLC [&lt;ulink linkType="reference" linkID="249700"&gt;249700&lt;/ulink&gt;], and two primary degradation products, an aggregate at 400 kDa and a product at 33 kDa, were detected. The pH profile indicated that pH 6 was the optimal pH. At elevated temperatures of 40 degrees C, the percentage of aggregation increased. The presence of 10% manitol appeared to confer a protective effect against the amount of aggregation occurring. However, the amount of the smaller, 30 kDa product was not affected by manitol, but was primarily determined by the temperature.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxicity data have been reported for AL-901. Theoretically, some chimeric antibodies can be immunogenic in humans, although this is less than with entirely murine antibodies. Possible consequences of repetitive administration of MAbs are serum sickness, reduced efficacy and, although unlikely, induction of anti-idiotype antibodies with potential basophil and mast cell degranulation [&lt;ulink linkType="reference" linkID="249702"&gt;249702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A double-blind, placebo-controlled, single dose study, was conducted in 33 pollen-sensitive asthmatics, who had high levels of serum IgE. Single doses of 3, 10, 30 and 100 mg of AL-901 were given iv. Serum IgE decreased in a dose-dependent manner with suppression reaching 96% after 100 mg. The time of recovery to 50% of baseline IgE was also dose-dependent, ranging from 1.3 days for the 3 mg dose, to 39 days for the 100 mg dose. Complexed IgE was eliminated at a rate which was comparable with the half-life of AL-901 (11 - 13 days at all doses) [&lt;ulink linkType="reference" linkID="258775"&gt;258775&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A randomized, placebo-controlled trial of AL-901 in the USA [&lt;ulink linkType="reference" linkID="191533"&gt;191533&lt;/ulink&gt;], involved 155 volunteers suffering from seasonal allergic rhinitis. Inclusion criteria included a history of  seasonal allergic rhinitis, high blood IgE levels and positive responses to an extract of mountain cedar pollen in skin tests. The objective was to evaluate the safety and tolerability of  three dose levels of AL-901, and to assess the efficacy of reducing allergic symptoms. Results showed a reduction in the severity and duration of nasal symptoms and a reduction in the use of rescue medications [&lt;ulink linkType="reference" linkID="191533"&gt;191533&lt;/ulink&gt;], as compared to placebo. The major limitation of this study is that no comparison was made to nasal steroids, which are known to be quite effective in the majority of patients with seasonal allergic rhinitis.&lt;/para&gt;&lt;para&gt;A phase IIa, placebo-controlled study in approximately 320 patients with mild to moderate asthma, high IgE and positive skin tests to mites, cockroaches, dog or cat was initiated [&lt;ulink linkType="reference" linkID="206946"&gt;206946&lt;/ulink&gt;]. The aims were to evaluate efficacy on asthma symptoms, pulmonary function tests, and to evaluate the safety and tolerability of multiple doses of AL-901.&lt;/para&gt;&lt;para&gt;In light of the recent agreement between Tanox and &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt;-Roche, it is important to consider the results obtained in humans, by &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt;, with another humanized anti-IgE MAb, E25. Two relatively similar studies have been conducted to evaluate the effect of E25 on the allergic airway responsiveness of adult asthmatics. It has been shown [&lt;ulink linkType="reference" linkID="258786"&gt;258786&lt;/ulink&gt;] that E25 can reduce the early- and late-response to allergen and provoke an increased dose of allergen that is required to induce such responses [&lt;ulink linkType="reference" linkID="258784"&gt;258784&lt;/ulink&gt;]. It is interesting to note that the iv administration of E25 partially blocked the response to allergen, with patients still experiencing an average fall of forced expiratory volume of 18%, at 1 sec [&lt;ulink linkType="reference" linkID="258786"&gt;258786&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;No data are available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;None have been reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent Commentary&lt;/subtitle&gt;In 1995, Tanox obtained a patent, EP-00407392B (WO-09111456) [&lt;ulink linkType="reference" linkID="180511"&gt;180511&lt;/ulink&gt;] covering anti-IgE antibodies. Also in 1995, Tanox was granted two patents in the USA, covering both therapeutic use and a method of producing its anti-IgE antibodies [&lt;ulink linkType="reference" linkID="180513"&gt;180513&lt;/ulink&gt;]. Although murine antibodies with similar properties were described as early as 1981, Tanox discovered their therapeutic potential, characterized their unique properties and developed genetically engineered forms of the antibodies as products suitable for human use [&lt;ulink linkType="reference" linkID="258540"&gt;258540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A three-year-old lawsuit, between Tanox and &lt;ulink linkType="Company" linkID="19453"&gt;Genentech&lt;/ulink&gt; (Roche), related to their respective research programs on anti-IgE antibodies, has been recently settled and both parties have agreed to codevelop anti-IgE compounds [&lt;ulink linkType="reference" linkID="226408"&gt;226408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;AL-901 appears to have all of the characteristics of a useful anti-IgE MAb, however, more data on a larger population of patients, and safety data on prolonged exposure would be desirable before recommending AL-901 for regular use. In addition, in order to be competitive as an asthma therapy, AL-901 will have to show equivalent or better efficacy when compared to inhaled steroids, or show a favorable cost benefit ratio or an easier route of administration (ie, oral rather than parenteral or inhaled delivery). Assuming that IgE blockade and reduction have long lasting benefits, AL-901 may also be useful in the treatment of conditions characterized by high IgE production, such as rhinitis, atopic dermatitis, food allergies and insect allergies. Since the last two conditions can be life-threatening, manufacturers might consider fast track development of AL-901 for these indications.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>1999-04-21T00:00:00.000Z</StatusDate><Source id="322048" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1999-04-21T00:00:00.000Z</StatusDate><Source id="322048" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24437">Ciba-Geigy AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1997-09-19T00:00:00.000Z</StatusDate><Source id="263801" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24437">Ciba-Geigy AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1997-09-19T00:00:00.000Z</StatusDate><Source id="263801" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24437">Ciba-Geigy AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>1997-09-19T00:00:00.000Z</StatusDate><Source id="263801" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1999-04-21T00:00:00.000Z</StatusDate><Source id="322048" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="507">Immediate type hypersensitivity</Indication><StatusDate>2005-03-14T00:00:00.000Z</StatusDate><Source id="596927" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>1999-04-21T00:00:00.000Z</StatusDate><Source id="322048" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="249702" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate><Source id="277691" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1994-11-01T00:00:00.000Z</StatusDate><Source id="180397" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24437">Ciba-Geigy AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>1995-02-01T00:00:00.000Z</StatusDate><Source id="180364" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="507">Immediate type hypersensitivity</Indication><StatusDate>1999-07-14T00:00:00.000Z</StatusDate><Source id="331745" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24437">Ciba-Geigy AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>1994-11-01T00:00:00.000Z</StatusDate><Source id="180397" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24437">Ciba-Geigy AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate><Source id="277691" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="20318">Tanox Inc</OwnerCompany><Country id="US">US</Country><Indication id="507">Immediate type hypersensitivity</Indication><AwardedIndication>Treatment of patients with peanut allergies</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2002-09-24T00:00:00.000Z</MileStoneDate><Source id="464974" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01006"><Name>Immunoglobulin E</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1060017">The Peanut Foundation</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="21">Patent - Litigation Settlement</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="127614" title="The Peanut Foundation to provide funding to Tanox for talizumab"/><Deal id="127615" title="Ciba to obtain rights to Tanox's talizumab"/><Deal id="180635" title="3-party agreement for Xolair anti-IgE antibody       "/></Deals><PatentFamilies><PatentFamily id="1159830" number="WO-09420533" title="Peptides representing antigenic epitopes of ige present on b cell but not basophil surface."/><PatentFamily id="1979773" number="WO-00151076" title="Administering Ige Antagonists During Pregnancy To Ameliorate Allergic Diseases In The Offspring"/><PatentFamily id="2360114" number="WO-2006065746" title="Methods of treating ige-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations"/><PatentFamily id="2465877" number="WO-2013020132" title="Methods of treating cardiovascular and metabolic diseases"/><PatentFamily id="3353829" number="WO-2004091658" title="High concentration antibody and protein formulations"/><PatentFamily id="429960" number="US-06787524" title="Cpg oligonucleotides and related compounds for enhancing adcc induced by anti-ige antibodies"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>